2nd Quit-Smoking Drug Gets FDA's OK

(AP)  A Pfizer Inc. drug shown to help more than one in five smokers quit the habit received federal approval on Thursday, adding another option to the limited pool of effective stop-smoking prescription medicines.

Varenicline is only the second nicotine-free smoking cessation drug to gain Food and Drug Administration approval. Pfizer plans to market the twice-daily tablet as Chantix.

"It's a welcome new addition. It's like with cancer or heart disease or high blood pressure or diabetes: The more effective treatments you have, the better off patients are," said Dr. Steven Schroeder, a professor of medicine at the University of California, San Francisco, who is active in smoking cessation efforts.

Varenicline works in two ways — by cutting the pleasure of smoking and reducing the withdrawal symptoms that lead smokers to light up again and again.

Most other stop-smoking drugs are various nicotine-replacement therapies, sold by prescription and over the counter in gum, patch, lozenge, nasal spray or inhaler form. In 1997, the FDA approved bupropion, an antidepressant already sold as Wellbutrin but rebranded as Zyban, an anti-smoking drug.

Several studies conducted in Europe on about 2,000 smokers and presented in November at an American Heart Association conference showed that a year after initial treatment with varenicline, abstinence rates were 22 percent, versus 16 percent among those given Zyban. Just 8 percent of those given dummy medicines had stopped after a year.

The approved course of Chantix treatment is 12 weeks, a period that can be doubled in patients who successfully quit to increase the likelihood they will remain smoke-free, the FDA said.

Other clinical trials show the drug's effect is more pronounced in the short term: 44 percent of patients quit smoking following a 12-week course of treatment with Chantix, compared with the 30 percent of Zyban patients who quit, according to Pfizer. However, smoking cessation experts said the longer-term data are more applicable, given the difficulty of quitting the habit for good.

"It's not going to be a revolution; it's going to be a substantial step forward," Thomas Glynn, director of cancer science and trends at the American Cancer Society, said of varenicline. Glynn added that the greatest value will be for smokers who have tried Zyban or nicotine-replacement therapy but failed to quit.

"My bet is that it will work as well as they do and, from the look of things, a little bit better," he said.

Pfizer had predicted Chantix's annual sales would reach $1 billion.

"$1 billion in sales is plausible but I'd rather be conservative," said Barbara Ryan, an analyst at Deutsche Bank who is predicting $500 million in annual sales by 2009.

Ryan said Pfizer has it has the benefit of a large sales force and a huge market potential. Plus, she expects insurance will cover the drug because complications stemming from smoking are such expensive health problems.

• 1
• 2
• Next Page »